ImmunoCellular Therapeutics


Stock Update (NYSE MKT:IMUC): ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing ICT-107 to Phase 3 Registrational Trial

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) issued the following letter to shareholders. To Our Shareholders: As we work toward building a leading cancer immunotherapy company, …

Roth Capital Reiterates Bullish Stance On ImmunoCellular Therapeutics Following SPA Agreement With FDA

In a research report released earlier today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of ImmunoCellular Therapeutics (NYSEMKT:IMUC) with …

Stock Update (NYSE MKT:IMUC): ImmunoCellular Therapeutics Ltd Establishes Agreement with Pure MHC for Novel Quality Control Assay for ICT-107 Phase 3 Registrational Trial

ImmunoCellular Therapeutics Ltd (NYSE MKT:IMUC) announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality …

Stock Update (NYSE MKT:IMUC): ImmunoCellular Therapeutics Ltd Enters into Manufacturing Agreement with PCT LLC for US Production of ICT-107 for Phase 3 Registration Trial

ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC) announced the selection of PCT, LLC, a subsidiary of Caladrius Biosciences, Inc., as the US manufacturer for ImmunoCellular’s …

Company Update (NYSE:IMUC): ImmunoCellular Therapeutics Announces Pricing of a Public Offering of Common Stock and Warrants

ImmunoCellular Therapeutics (NYSE:IMUC) announced that it has priced an underwritten public offering of an aggregate of 26,650,000 shares of its common stock at …

IMUC: ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 9, 2015

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE:IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the …

Maxim Maintains Buy On ImmunoCellular Following Positive Regulatory Feedback From EMA

In a research report published Monday, Maxim Group analyst Jason Kolbert maintained a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a $4.00 price …

Maxim Maintains Buy On ImmunoCellular Following SNO Data Review

In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a $4 price target, …

Maxim Reiterates Buy On ImmunoCellular As ICT107 Phase 2 Data Continues To Show Benefit

In a research report sent to investors today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a …

Maxim Maintains Buy On ImmunoCellular Following 3Q14 Update

In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on ImmunoCellular Therapeutics (NYSE :IMUC) with a price …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts